1. Change in APOC3 level in response to treatment with APOC3 antisense oligonucleotide ISIS Phase 2, randomised, double-blind, placebo-controlled study
Mean Percentage Change in APOC3 Level
placebo
ISIS , 100 mg
ISIS , 200 mg
ISIS , 300 mg
Treatment period
Study Day
Adapted from: Gaudet et al., NEJM 2015

2. Change in triglyceride level in response to treatment with APOC3 antisense oligonucleotide ISIS Phase 2, randomised, double-blind, placebo-controlled study
Mean Percentage Change in Triglyceride Level
Treatment period
placebo
ISIS , 100 mg
ISIS , 200 mg
ISIS , 300 mg
Study Day
Adapted from: Gaudet et al., NEJM 2015